Company Description
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer.
The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma.
The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers.
TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
| Country | United States |
| Founded | 2010 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 112 |
| CEO | Ms. Mary T. Szela B.S.N., M.B.A. |
Contact Details
Address: 6272 West 91st Avenue Westminster, Colorado 80031 United States | |
| Phone | 415 336 8917 |
| Website | trisaluslifesci.com |
Stock Details
| Ticker Symbol | TLSI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001826667 |
| CUSIP Number | 054603105 |
| ISIN Number | US89680M1018 |
| Employer ID | 85-3009869 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Mary T. Szela B.S.N., M.B.A. | Chief Executive Officer, President and Director |
| Sean Edward Murphy | Chief Financial Officer and Director |
| Dr. Steven C. Katz F.A.C.S., M.D. | Chief Medical Officer and Chairman of Scientific Advisory Board |
| Jennifer L. Stevens J.D. | Chief Regulatory Officer |
| Lori Ann Santamaria | Vice President of Operations |
| Dr. Bryan F. Cox Ph.D. | Chief Scientific and Manufacturing Officer |
| James E. Young | Senior Vice President of Investor Relations and Treasurer |
| Rachel Garcia | Marketing Manager |
| Dr. Richard B. Marshak M.B.A., MBA, VMD | Senior Vice President of Corporate Development and Strategy |
| Jodi Devlin | President of Commercial Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | POS AM | Post-Effective amendments for registration statement |
| Apr 17, 2024 | POS AM | Post-Effective amendments for registration statement |
| Apr 16, 2024 | 8-K | Current Report |
| Apr 11, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 11, 2024 | 10-K | Annual Report |
| Apr 2, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Apr 1, 2024 | 8-K | Current Report |
| Mar 12, 2024 | 8-K | Current Report |
| Jan 25, 2024 | 424B3 | Prospectus |
| Jan 25, 2024 | 424B3 | Prospectus |